Researchers have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment, similar to that approved by the FDA to treat other conditions. The findings point to the possibility of developing such immunotherapies for heart failure in patients who have experienced a heart attack or other injury.
